Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

ADMA Biologics Shares Gain As Interim Q4 Sales Beat Expectation

ADMA Biologics Inc (NASDAQ:ADMA) expects Q4 Sales of approximately $26 million, compared to $14 million a year ago and better than the consensus of $21.76 million. 

  • The preliminary results represent the Company's highest quarterly revenue since its inception. 
  • For FY21, the revenues are anticipated to be approximately $81 million, almost double from $42 million in FY20.
  • "Following the successful establishment of end-to-end control of its most critical manufacturing and supply chain functions, coupled with a substantial expansion of its production capacity, 2021 was a foundational year for ADMA, culminating in a year-exiting annualized revenue run rate over $100 million," said Adam Grossman, President and CEO.
  • The Company remains on track to have ten or more plasma collection centers FDA-licensed by year-end 2023. 
  • As previously disclosed, ADMA has engaged Morgan Stanley as an advisor to evaluate various strategic and financing alternatives.
  • Price Action: ADMA shares are up 7.30% at $1.47 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.